MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- TORRENT PHARMACEUTICALS LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Torrent Pharma Quarterly Results (TORR)
Here are the latest quarterly results of Torrent Pharma. For more details, see the Torrent Pharma financial fact sheet and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
Torrent Pharma Quarterly Results
| No. of Mths Qtr. Ending |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 14,290 | 14,770 | 17,220 | 18,720 | 18,940 | 20,510 | 18,560 | 20,220 | |
| Other income | Rs m | 780 | 740 | 420 | 270 | 100 | 30 | 170 | 200 | |
| Turnover | Rs m | 15,070 | 15,510 | 17,640 | 18,990 | 19,040 | 20,540 | 18,730 | 20,420 | |
| Expenses | Rs m | 11,000 | 11,180 | 13,580 | 13,950 | 14,210 | 14,900 | 13,830 | 14,810 | |
| Gross profit | Rs m | 3,290 | 3,590 | 3,640 | 4,770 | 4,730 | 5,610 | 1,160 | 5,410 | |
| Depreciation | Rs m | 840 | 940 | 1,510 | 1,500 | 1,520 | 1,560 | 1,600 | 1,600 | |
| Interest | Rs m | 510 | 800 | 1,210 | 1,220 | 1,260 | 1,330 | 1,230 | 1,220 | |
| Profit before tax | Rs m | 2,720 | 2,590 | 1,340 | 2,320 | 2,050 | 2,750 | -1,500 | 2,790 | |
| Tax | Rs m | 680 | 2,010 | -940 | 690 | 260 | 290 | 20 | 630 | |
| Profit after tax | Rs m | 2,040 | 580 | 2,280 | 1,630 | 1,790 | 2,460 | -1,520 | 2,160 | |
| Gross profit margin | % | 23.0 | 24.3 | 21.1 | 25.5 | 25.0 | 27.4 | 6.3 | 26.8 | |
| Effective tax rate | % | 25.0 | 77.6 | -70.1 | 29.7 | 12.7 | 10.5 | -1.3 | 22.6 | |
| Net profit margin | % | 14.3 | 3.9 | 13.2 | 8.7 | 9.5 | 12.0 | -8.2 | 10.7 | |
| Diluted EPS | Rs | 12.1 | 3.4 | 13.5 | 9.6 | 10.6 | 14.5 | -9.0 | 12.8 | |
| Diluted EPS (TTM) | Rs | 48.9 | 38.8 | 40.1 | 38.6 | 37.1 | 48.2 | 25.8 | 28.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Torrent Pharma 1QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: DIVIS LABORATORIES CADILA HEALTHCARE WYETH LTD FULFORD INDIA BIOCON
Compare TORRENT PHARMA With: DIVIS LABORATORIES CADILA HEALTHCARE WYETH LTD FULFORD INDIA BIOCON
Compare TORRENT PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)
Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.
Views on news
TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)
Jul 25, 2019 | Updated on Jul 25, 2019For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)
May 22, 2019 | Updated on May 22, 2019For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)
Oct 14, 2019This is once in a decade opportunity to make a killing from smallcap rebound.
Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)
Oct 7, 2019Here's what every individual investor must know about Yes Bank...
Rebound Riches Could be Yours With These Stocks (Profit Hunter)
Oct 4, 2019The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.
The One Stock I Like in this Market (The 5 Minute Wrapup)
Oct 10, 2019There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?
5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)
Oct 11, 2019Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.
More|
| |
TORRENT PHARMA SHARE PRICE
Oct 16, 2019 (Close)
TRACK TORRENT PHARMA
- Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON TORRENT PHARMA
TORRENT PHARMA - PFIZER COMPARISON
COMPARE TORRENT PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.